


## GC Pharma taps AI expert to expand hemophilia franchise

18 September 2020 | News

**The partnership will develop new drug programs that advance GC Pharma's global leadership in hemophilia and additional disease areas**



Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery based in the US, has announced a partnership with GC Pharma, a South Korean biopharmaceutical company formerly known as Green Cross Corporation, to discover and develop novel hemophilia therapies. GC Pharma is a pioneer in vaccines and protein therapeutics and has long been dedicated to research and development of hemophilia treatments, currently developing its non-factor therapy for hemophilia A.

GC Pharma's partnership with Atomwise will enable the expansion of its hemophilia business and launch multiple discovery programs to develop a small molecule therapy for hemophilia and other indications.

Hemophilia treatment has largely remained the same for several decades with the standard of care in the form of infusion therapy to replenish factor proteins which unfortunately have short half-lives. A selective small molecule targeting a key anticoagulant is a promising and novel approach to restore normal hemostasis and provides a far more convenient therapeutic option for hemophilia patients.

Under the agreement, GC Pharma and Atomwise will explore potential targets with the goal to develop a small molecule, and orally administrable drug option for patients.

This first and other subsequent targets will be virtually screened for small molecules using AtomNet®, Atomwise's AI platform for drug discovery. The AtomNet® platform is able to screen 16 billion compounds for potential hits in less than two days, dramatically accelerating the early drug discovery process, which otherwise can take months or years to complete. Researchers who have collaborated with Atomwise using the AtomNet® platform have experienced a greater than 75 percent success rate identifying hits on targets across numerous disease applications.